AngioDynamics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AngioDynamics (ANGO).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$17Upside to Avg. PT+52.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$19→$18
Oct 9, 2026	Canaccord Genuity	John Young	Maintained	Buy	$20
Jul 15, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$16→$19
Jul 15, 2026	Canaccord Genuity	John Young	PT Raise	Buy	$16→$20
Apr 6, 2026	Freedom Broker	Ilya Zubkov	Initiate	Buy	$16
Apr 6, 2026	Canaccord Genuity	John Young	PT Cut	Buy	$18→$16
Oct 3, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$17→$18
Jul 16, 2025	Lake Street	Frank Takkinen	Initiate	Buy	$24
Jul 16, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$16
Jul 16, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$15→$17
Apr 7, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$15→$16
Jan 10, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$14→$15
Jan 9, 2025	Canaccord Genuity	William Plovanic	PT Raise	Buy	$12→$15
Dec 10, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$14
Oct 4, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$14
Oct 4, 2024	Canaccord Genuity	William Plovanic	PT Cut	Buy	$13→$12
Sep 20, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$14
Jul 17, 2024	Canaccord Genuity	William Plovanic	PT Cut	Buy	$18→$13
Jul 17, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$14
May 22, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$14

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $19 to $18.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $19.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.

Benzinga Newsdesk

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Avi Kapoor

AngioDynamics Eyes Growth Despite Tariffs

AngioDynamics (ANGO) exceeds expectations, raises guidance for fiscal 2026 with positive cash flow expected.

Triveni Kothapalli

AngioDynamics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AngioDynamics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics Eyes Growth Despite Tariffs

People Also Watch

People Also Watch

AngioDynamics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

AngioDynamics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

PROHC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

PROCanaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

PROCanaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics Eyes Growth Despite Tariffs

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

PRO
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

PRO
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16